Developments in immunotherapy for gastrointestinal cancer

Area of Science:

• Gastrointestinal Oncology
• Cancer Immunology
• Translational Cancer Research

Background:

• Gastrointestinal cancers, particularly colorectal cancer (CRC), represent a significant global health burden.
• Most CRC patients are diagnosed at advanced stages, leading to poor prognoses due to chemotherapy resistance and metastasis.
• Current 5-year survival rates for advanced CRC are critically low, highlighting the urgent need for novel therapeutic strategies.

Purpose of the Study:

• To review advances in immunotherapy for colorectal cancer (CRC).
• To discuss the tumor microenvironment's role in immune evasion and chemotherapy resistance.
• To examine current and prospective immunotherapeutic strategies for CRC.

Main Methods:

• Review of basic immunology and the colorectal tumor microenvironment.
• Analysis of current FDA-approved immunotherapies, including monoclonal antibodies (mAb), vaccines, adoptive cell therapy, cytokines, and checkpoint inhibitors.
• Examination of prior research, ongoing clinical trials, and preclinical studies in murine models.

Main Results:

• The tumor microenvironment presents significant obstacles to effective immune responses and chemotherapy.
• Targeted immunotherapies are being developed to overcome these obstacles and enhance anti-tumor immunity.
• Various immunotherapeutic approaches, including mAbs and checkpoint inhibitors, show promise in preclinical and clinical settings.

Conclusions:

• Immunotherapy is a rapidly evolving and crucial area for improving outcomes in colorectal cancer.
• Understanding tumor immunology and microenvironment is key to developing effective targeted therapies.
• Continued research and clinical trials are essential to define future strategies for CRC immunotherapy.